Therapeutic targeting of the oncostatin M receptor-β prevents inflammatory heart failure
- 969 Downloads
Heart failure (HF) is a common and potentially deadly condition, which frequently develops as a consequence of various diseases of the heart. The incidence of heart failure continuously increases in aging societies illustrating the need for new therapeutic approaches. We recently discovered that continuous activation of oncostatin M (OSM), a cytokine of the interleukin-6 family that induces dedifferentiation of cardiomyocytes, promotes progression of heart failure in dilative cardiomyopathy. To evaluate whether inhibition of OSM signaling represents a meaningful therapeutic approach to prevent heart failure we attenuated OSM-receptor (Oβ) signaling in a mouse model of inflammatory dilative cardiomyopathy. We found that administration of an antibody directed against the extracellular domain of Oβ or genetic inactivation of a single allele of the Oβ gene reduced cardiomyocyte remodeling and dedifferentiation resulting in improved cardiac performance and increased survival. We conclude that pharmacological attenuation of long-lasting Oβ signaling is a promising strategy to treat different types and stages of HF that go along with infiltration by OSM-releasing inflammatory cells.
KeywordsDedifferentiation Dilative cardiomyopathy Cytokine Cell survival program Myoglobin Insulin growth factor-1 (IGF-1)
The authors thank Jutta Wetzel, Kerstin Richter, Brigitte Matzke and Marion Wiesnet for excellent technical assistance. This work was supported by the Max-Planck-Society, the Excellence Cluster Cardiopulmonary System (ECCPS), the University of Giessen-Marburg Lung Center (UGMLC), and the German Center for Cardiovascular Research (DZHK). The authors declare that they have no conflicting commercial interests related to this work.
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Supplementary material 2 (MPG 9494 kb)
- 2.Ahmad S, Rai TS, Khullar M, Bahl A, Saikia UN, Thungapathra M, Kumar RM, Mahajan R, Talwar KK (2010) Decreased myocardial expression of dystrophin and titin mRNA and protein in dilated cardiomyopathy: possibly an adverse effect of TNF-alpha. J Clin Immunol 30:520–530. doi: 10.1007/s10875-010-9388-3 PubMedCrossRefGoogle Scholar
- 13.Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss H-P, Tschope C, Van Bilsen M, Zannad F, McMurray J, Shah AM (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the translational research committee of the heart failure association of the European society of cardiology. Eur J Heart Fail 11:119–129. doi: 10.1093/eurjhf/hfn043 PubMedCrossRefGoogle Scholar
- 19.Kubin T, Poling J, Kostin S, Gajawada P, Hein S, Rees W, Wietelmann A, Tanaka M, Lorchner H, Schimanski S, Szibor M, Warnecke H, Braun T (2011) Oncostatin m is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell 9:420–432 pii: S1934-5909(11)00394-8PubMedCrossRefGoogle Scholar
- 20.Kubin T, Tomars M, Fach C, Hein S, Bramlage P, Shim GJ, Scholz D, Kostin S, Zimmermann R, Elsasser A, Schaper W, Schaper J (2005) Transforming growth factor-beta1 downregulates beating frequency and remodeling of cultured rat adult cardiomyocytes. Cell Tissue Res 321:57–66PubMedCrossRefGoogle Scholar
- 21.Maier HJ, Schips TG, Wietelmann A, Kruger M, Brunner C, Sauter M, Klingel K, Bottger T, Braun T, Wirth T (2012) Cardiomyocyte-specific I kappa B kinase (IKK)/NF-kappa B activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci USA 109:11794–11799. doi: 10.1073/pnas.1116584109 PubMedCrossRefGoogle Scholar
- 24.Poling J, Gajawada P, Lorchner H, Polyakowa V, Szibor M, Bottger T, Warnecke H, Kubin T, Braun T (2012) The Janus face of OSM mediated cardiomyocyte dedifferentiation during cardiac repair and disease. Cell Cycle 11. pii:19024Google Scholar
- 27.Weiss TW, Speidl WS, Kaun C, Rega G, Springer C, Macfelda K, Losert UM, Grant SL, Marro ML, Rhodes AD, Fuernkranz A, Bialy J, Ullrich R, Holzmann P, Pacher R, Maurer G, Huber K, Wojta J (2003) Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res 59:628–638PubMedCrossRefGoogle Scholar
- 28.Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang WZ, Mori C, Shiota K, Yoshida N, Kishimoto T (1996) Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 93:407–411PubMedCrossRefGoogle Scholar